Rentschler
Rentschler Biopharma is a CRO & CDMO brand from Germany.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Rentschler Biopharma SE is a privately held German contract development and manufacturing organization (CDMO) headquartered in Laupheim, in the Biberach district of Upper Swabia. The company develops and manufactures biopharmaceutical products for other pharmaceutical and biotechnology companies, serving programs from early development and clinical supply through commercial production. Its capabilities cover cell-line and process development, analytical development, formulation, filling, quality control, quality assurance, regulatory support and GMP manufacturing. The business traces its roots to a pharmacy established in Laupheim in 1872 by pharmacist Gottlob Müller. The pharmacy passed to Erwin Rentschler Sr., the founder's son-in-law, in 1909 and remained associated with the Rentschler family for approximately a century before being sold in 2012. The industrial foundation of the present group emerged during the night of New Year's Eve 1923–24, when Erwin Rentschler Jr. developed the formulation for the painkiller Melabon. Demand outgrew the pharmacy, leading to the establishment of Dr. Rentschler & Co. OHG in 1927. The original business expanded from over-the-counter medicines into prescription products and veterinary vaccines. A major strategic shift occurred in 1974, when Friedrich Erwin Rentschler created a biotechnology division and began work on interferons. That effort resulted in the 1983 approval of Fiblaferon, described by the company history as the world's first approved natural interferon-beta therapeutic. In 1993 the biotechnology activities were consolidated into Rentschler Biotechnologie GmbH, and from 1997 the organization increasingly concentrated on development and manufacturing services for biopharmaceutical products rather than on a broad proprietary medicines portfolio. Following a management transition from Friedrich E. Rentschler to his son Nikolaus F. Rentschler in 1999, the group accelerated its biotechnology focus. The corporate structure was reorganized under Dr. Rentschler Holding GmbH & Co. KG in 2003. Manufacturing capacity in Germany expanded during the 2000s, reaching nine units for GMP production intended for clinical development and commercial supply by 2010. The operating company adopted the name Rentschler Biopharma SE in October 2017. Rentschler subsequently expanded internationally. In January 2019 it acquired a former Baxalta manufacturing facility in Milford, Massachusetts, creating the Rentschler Biopharma Manufacturing Center US. An adjacent expansion was planned to add approximately 2,050 square metres of cleanroom space and four 2,000-litre single-use bioreactors, with an emphasis on commercial production of complex molecules for customers in the United States. In February 2021, the company established Rentschler ATMP Ltd. in the United Kingdom as a center of excellence for advanced therapy medicinal products, including cell and gene therapy development and manufacturing. The company also became involved in the COVID-19 vaccine supply chain. During 2020, it performed purification work for the messenger RNA used in BioNTech's Comirnaty vaccine. According to the referenced company history, Rentschler Biopharma's involvement extended to production associated with more than one billion vaccine doses. In addition to its commercial activities, the Rentschler family and holding organization support academic, civic and philanthropic initiatives in the Laupheim, Biberach and Ulm region, including engagement connected with the Albert Einstein Discovery Center and the University of Applied Sciences in Biberach.
History
Rentschler Biopharma's history combines a family pharmacy, proprietary medicines and a later specialization in biopharmaceutical contract services. The earliest predecessor was a pharmacy founded in Laupheim in 1872 by pharmacist Gottlob Müller. In 1909, ownership passed to pharmacist Erwin Rentschler Sr., whose family continued to operate the pharmacy, later known as the 7-Schwaben-Apotheke. The pharmacy was eventually sold in 2012 after roughly 140 years of Rentschler family ownership. The foundation for the industrial business was laid at the end of 1923. While working a night shift at the pharmacy, Erwin Rentschler Jr. developed a painkiller formulation that was marketed as Melabon. The product's demand exceeded the pharmacy's capacity, prompting the creation of Dr. Rentschler & Co. OHG in 1927, with Erwin Rentschler Jr. as managing director. His brother, pharmacist and chemist Helmut Rentschler, joined as managing partner in 1929. The company initially depended heavily on the single analgesic product but gradually added other non-prescription medicines. Diversification began in 1947 with the establishment of the Warthausen Bacteriological Institute, which developed and produced veterinary vaccines. After Erwin Rentschler Jr. died in 1959, his son Friedrich Erwin Rentschler assumed management. Under Friedrich's leadership, the business expanded its medicines portfolio, adding prescription products, especially in cardiovascular care. In 1974 he established a biotechnology division and initiated work on interferons, creating the scientific and commercial basis for the group's later transformation. The interferon program led to the 1983 approval of Fiblaferon, identified in the referenced history as the first approved natural interferon-beta therapeutic worldwide. In 1993, the biotechnology operations were brought together in Rentschler Biotechnologie GmbH. From 1997 onward, the company increasingly focused on providing development and manufacturing services to developers of biopharmaceutical products, moving away from the diversified pharmaceutical model of its earlier decades. Friedrich E. Rentschler transferred management to his son Nikolaus F. Rentschler in 1999. The group then concentrated its activities on biotechnology and expanded production infrastructure. A group-level restructuring in 2003 placed the businesses under Dr. Rentschler Holding GmbH & Co. KG, with Rentschler Biotechnologie representing the largest operating unit. By 2010, the German operation had nine units for GMP production of biopharmaceuticals intended for clinical development and commercial supply. Nikolaus F. Rentschler later became Chairman of the Supervisory Board in January 2016. In October 2017, Rentschler Biotechnologie GmbH was renamed Rentschler Biopharma SE. The company then began a more explicit international expansion. In January 2019, it acquired a former Baxalta production facility in Milford, Massachusetts. The site, known as the Rentschler Biopharma Manufacturing Center US, was intended to give the company a stronger North American presence and provide additional capacity for cGMP manufacturing. Plans for an adjacent facility included approximately 2,050 square metres of cleanroom space and four automated 2,000-litre single-use bioreactors, with production aimed particularly at complex molecules for United States customers. During the COVID-19 pandemic, Rentschler contributed to the manufacturing network for BioNTech's Comirnaty vaccine. Its role involved purification of the vaccine's mRNA. The company history states that Rentschler was involved in production associated with more than one billion doses, making the program one of the most visible examples of its large-scale biopharmaceutical manufacturing role. In February 2021, Rentschler ATMP Ltd. was founded in the United Kingdom. The entity was designed as a center of excellence for advanced therapy medicinal products, extending the group's capabilities into cell and gene therapy development and production. Alongside its business operations, the Rentschler family and holding group have supported academic and civic initiatives in southern Germany, including activities in Laupheim, the Biberach area and Ulm.
- 2021
Rentschler ATMP founded in the United Kingdom
[1]A UK center of excellence for cell and gene therapy and other advanced therapy medicinal products was established.
- 2020
Comirnaty manufacturing involvement
[1]Rentschler performed mRNA purification work for BioNTech's Comirnaty vaccine.
- 2019
United States expansion
[1]The company acquired a former Baxalta production facility in Milford, Massachusetts, and planned a larger adjacent manufacturing center.
- 2017
Operating company renamed Rentschler Biopharma SE
[1]Rentschler Biotechnologie GmbH adopted the Rentschler Biopharma SE name.
- 2010
German GMP manufacturing network expanded
[1]Nine units were available for GMP production of biopharmaceuticals for clinical development and commercial supply.
- 2003
Group reorganized under Rentschler Holding
[1]The corporate group was restructured under Dr. Rentschler Holding GmbH & Co. KG.
- 1997
Shift toward biopharmaceutical services
[1]The company increasingly concentrated on development and manufacturing services for biopharmaceutical products.
- 1993
Biotechnology activities consolidated
[1]The group's biotechnology activities were merged into Rentschler Biotechnologie GmbH.
- 1983
Fiblaferon receives approval
[1]Fiblaferon, a natural interferon-beta therapeutic, received approval and became a landmark in the company's biotechnology history.
- 1974
Biotechnology division created
[1]Friedrich Erwin Rentschler established a biotechnology division and began work on interferons.
Products and positioning
A specialist, privately held biopharmaceutical CDMO offering integrated development, GMP manufacturing and regulatory-quality support for complex biologics and advanced therapies.
Contract development · 1997
Biopharmaceutical development services
Rentschler supports biopharmaceutical developers from cell-line development through process development and analytical work. These services are intended to prepare biologic products for clinical manufacturing and later commercial production, integrating scientific development with manufacturing, quality and regulatory requirements.
Contract manufacturing
GMP biologics manufacturing
The company provides GMP production for biopharmaceutical medicines, including capacity for clinical-development material and commercial supply. Its manufacturing activities are supported by formulation, filling, analytical testing, quality control, quality assurance and regulatory affairs services.
Interferon-beta therapeutic · 1983
Fiblaferon
Fiblaferon was a natural interferon-beta product developed through Rentschler's biotechnology program. The referenced company history identifies its 1983 approval as a landmark, describing it as the world's first approved natural interferon-beta therapeutic.
mRNA vaccine manufacturing service · 2020
Comirnaty mRNA purification services
During the COVID-19 pandemic, Rentschler performed purification work for the mRNA used in BioNTech's Comirnaty vaccine. This was a manufacturing service performed for a partner rather than a Rentschler-owned vaccine brand.
Cell and gene therapy manufacturing · 2021
Advanced therapy medicinal product services
Through Rentschler ATMP Ltd. in the United Kingdom, the group offers a dedicated platform for development and production of advanced therapy medicinal products, including cell and gene therapy programs.
Brand decisions
2021
Establish a UK center for advanced therapiesStrategyBackground
Rentschler sought to extend its service portfolio beyond conventional biologics into cell and gene therapy and other advanced therapies.
Action taken
Rentschler ATMP Ltd. was founded in the United Kingdom as a center of excellence for development and production of advanced therapy medicinal products.
Aftermath
The move broadened the group's international platform and its capabilities for cell and gene therapy programs.
2020
Support production of the Comirnaty mRNA vaccineProduct launchBackground
The COVID-19 pandemic created urgent demand for manufacturing capacity for BioNTech's mRNA vaccine program.
Action taken
Rentschler provided purification services for the mRNA used in Comirnaty.
Aftermath
The company's history states that its work was associated with production of more than one billion vaccine doses.
2019
Acquire the former Baxalta Milford facilityM&ABackground
Rentschler sought international capacity and a stronger presence close to US-based biopharmaceutical customers.
Action taken
The company acquired a former Baxalta production facility in Milford, Massachusetts, and planned an adjacent Rentschler Biopharma Manufacturing Center US.
Aftermath
The expansion was intended to add approximately 2,050 square metres of cleanroom space and four 2,000-litre single-use bioreactors for cGMP production.
2017
Rename the operating company as Rentschler Biopharma SEStrategyBackground
The organization had developed from a biotechnology division into a specialized biopharmaceutical development and manufacturing provider.
Action taken
Rentschler Biotechnologie GmbH changed its name to Rentschler Biopharma SE.
Aftermath
The new name clarified the company's positioning as a biopharma-focused CDMO.
1997
Focus the business on biopharmaceutical development and manufacturing servicesStrategyBackground
Following the consolidation of biotechnology activities into Rentschler Biotechnologie GmbH, the group moved away from its earlier diversified medicines model and emphasized services for biopharmaceutical developers.
Action taken
The company concentrated its operating activities on development and manufacturing support for biopharmaceutical products.
Aftermath
This strategic direction became the foundation of the modern Rentschler Biopharma CDMO business.
Recent events
- 2021
Rentschler establishes a United Kingdom advanced-therapy center[1]
Other
Rentschler ATMP Ltd. was founded in the United Kingdom to provide development and manufacturing capacity for cell and gene therapies and other advanced therapy medicinal products.
- 2020
Rentschler supports production of BioNTech's Comirnaty vaccine[1]
Product launch · Other
The company performed purification work for the mRNA used in Comirnaty and became part of the manufacturing network for the first approved mRNA vaccine, according to the referenced company history.
- 2019
Rentschler expands into the United States through a Milford manufacturing site[1]
M&A
Rentschler acquired a former Baxalta production facility in the greater Boston area and began developing an adjacent manufacturing center to increase North American cGMP capacity.
- 2017
Rentschler Biotechnologie adopts the name Rentschler Biopharma SE[1]
Other
The company's biotechnology operating entity changed its corporate name to Rentschler Biopharma SE, reflecting its specialist biopharmaceutical development and manufacturing positioning.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/rentschler · Editorial policy · How profiles are compiled